Proficiency Testing of Epidermal Growth Factor Receptor Mutations Detection in Saliva Using Spectrum Saliva Collector (SDNA-1000) and Preservative Solution Detected by Electric Field-Induced Release and Measurement.
作者信息
Li Feng, Wei Fang, Grogan Tristan R, Elashoff David E, Vu David, Vigerust David J, Gupta Rohit, Wong David T W
机构信息
School of Dentistry, Division of Oral and Systemic Health Sciences, University of California Los Angeles, California, USA.
Department of Medicine Statistics Core, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
出版信息
Biopreserv Biobank. 2022 Oct;20(5):461-464. doi: 10.1089/bio.2022.0093. Epub 2022 Jul 26.
Abstract
摘要
相似文献
1
Proficiency Testing of Epidermal Growth Factor Receptor Mutations Detection in Saliva Using Spectrum Saliva Collector (SDNA-1000) and Preservative Solution Detected by Electric Field-Induced Release and Measurement.使用光谱唾液采集器（SDNA - 1000）和电场诱导释放与测量法检测的保存液对唾液中表皮生长因子受体突变进行能力验证测试。
Biopreserv Biobank. 2022 Oct;20(5):461-464. doi: 10.1089/bio.2022.0093. Epub 2022 Jul 26.
2
Electric Field-Induced Release and Measurement (EFIRM): Characterization and Technical Validation of a Novel Liquid Biopsy Platform in Plasma and Saliva.电场诱导释放和测量（EFIRM）：新型液体活检平台在血浆和唾液中的特征分析和技术验证。
J Mol Diagn. 2020 Aug;22(8):1050-1062. doi: 10.1016/j.jmoldx.2020.05.005. Epub 2020 Jun 1.
3
Noninvasive saliva-based EGFR gene mutation detection in patients with lung cancer.肺癌患者基于唾液的非侵入性表皮生长因子受体基因突变检测
Am J Respir Crit Care Med. 2014 Nov 15;190(10):1117-26. doi: 10.1164/rccm.201406-1003OC.
4
Ultra-Short Circulating Tumor DNA (usctDNA) in Plasma and Saliva of Non-Small Cell Lung Cancer (NSCLC) Patients.非小细胞肺癌（NSCLC）患者血浆和唾液中的超短循环肿瘤DNA（usctDNA）
Cancers (Basel). 2020 Jul 24;12(8):2041. doi: 10.3390/cancers12082041.
5
Clinical Features of Patients with an Epidermal Growth Factor Receptor T790M Mutation Detected in Circulating Tumor DNA.循环肿瘤 DNA 中检测到表皮生长因子受体 T790M 突变的患者的临床特征。
Oncology. 2020;98(1):23-28. doi: 10.1159/000502528. Epub 2019 Sep 6.
6
Correlation of epidermal growth factor receptor mutation status in plasma and tissue samples of patients with non-small cell lung cancer.非小细胞肺癌患者血浆和组织样本中表皮生长因子受体突变状态的相关性
J Cancer Res Ther. 2020 Jul-Sep;16(4):843-849. doi: 10.4103/jcrt.JCRT_515_18.
7
The predictive and prognostic significance of liquid biopsy in advanced epidermal growth factor receptor-mutated non-small cell lung cancer: A prospective study.液体活检在晚期表皮生长因子受体突变型非小细胞肺癌中的预测和预后意义：一项前瞻性研究。
Lung Cancer. 2019 Aug;134:187-193. doi: 10.1016/j.lungcan.2019.06.021. Epub 2019 Jun 24.
8
Saliva-derived cfDNA is applicable for EGFR mutation detection but not for quantitation analysis in non-small cell lung cancer.唾液衍生的 cfDNA 适用于非小细胞肺癌的 EGFR 突变检测，但不适用于定量分析。
Thorac Cancer. 2019 Oct;10(10):1973-1983. doi: 10.1111/1759-7714.13178. Epub 2019 Aug 23.
9
Liquid biopsy for detection of EGFR T790M mutation in nonsmall cell lung cancer: An experience of proficiency testing in Taiwan.液体活检检测非小细胞肺癌中的 EGFR T790M 突变：台湾的能力验证经验。
J Chin Med Assoc. 2019 Jun;82(6):473-476. doi: 10.1097/JCMA.0000000000000100.
10
[Comparison of epidermal growth factor receptor (EGFR) gene T790M mutation by droplet digital PCR and Super-ARMS PCR in plasma ctDNA samples of non-small cell lung cancer patients with the resistance to EGFR-tyrosine kinase inhibitor].[采用液滴数字PCR和超级扩增阻滞突变系统PCR检测对表皮生长因子受体（EGFR）酪氨酸激酶抑制剂耐药的非小细胞肺癌患者血浆循环肿瘤DNA样本中EGFR基因T790M突变的比较]
Zhonghua Bing Li Xue Za Zhi. 2018 Dec 8;47(12):910-914. doi: 10.3760/cma.j.issn.0529-5807.2018.12.003.
本文引用的文献
1
Ultra-Short Circulating Tumor DNA (usctDNA) in Plasma and Saliva of Non-Small Cell Lung Cancer (NSCLC) Patients.非小细胞肺癌（NSCLC）患者血浆和唾液中的超短循环肿瘤DNA（usctDNA）
Cancers (Basel). 2020 Jul 24;12(8):2041. doi: 10.3390/cancers12082041.
2
Electric Field-Induced Release and Measurement (EFIRM): Characterization and Technical Validation of a Novel Liquid Biopsy Platform in Plasma and Saliva.电场诱导释放和测量（EFIRM）：新型液体活检平台在血浆和唾液中的特征分析和技术验证。
J Mol Diagn. 2020 Aug;22(8):1050-1062. doi: 10.1016/j.jmoldx.2020.05.005. Epub 2020 Jun 1.
3
Electric Field-Induced Release and Measurement Liquid Biopsy for Noninvasive Early Lung Cancer Assessment.电场诱导释放和测量液体活检用于非侵入性早期肺癌评估。
J Mol Diagn. 2018 Nov;20(6):738-742. doi: 10.1016/j.jmoldx.2018.06.008. Epub 2018 Oct 8.
4
Evaluation of a novel saliva-based epidermal growth factor receptor mutation detection for lung cancer: A pilot study.新型唾液表皮生长因子受体基因突变检测用于肺癌的评估：一项初步研究。
Thorac Cancer. 2016 Jul;7(4):428-36. doi: 10.1111/1759-7714.12350. Epub 2016 May 13.
5
Evaluation and comparison of in vitro degradation kinetics of DNA in serum, urine and saliva: A qualitative study.血清、尿液和唾液中DNA体外降解动力学的评估与比较：一项定性研究。
Gene. 2016 Sep 15;590(1):142-8. doi: 10.1016/j.gene.2016.06.033. Epub 2016 Jun 16.
6
Circulating tumor DNA as a liquid biopsy for cancer.循环肿瘤 DNA 作为癌症的液体活检。
Clin Chem. 2015 Jan;61(1):112-23. doi: 10.1373/clinchem.2014.222679. Epub 2014 Nov 11.
7
Noninvasive saliva-based EGFR gene mutation detection in patients with lung cancer.肺癌患者基于唾液的非侵入性表皮生长因子受体基因突变检测
Am J Respir Crit Care Med. 2014 Nov 15;190(10):1117-26. doi: 10.1164/rccm.201406-1003OC.
8
Detection of exosomal biomarker by electric field-induced release and measurement (EFIRM).电场诱导释放和测量（EFIRM）检测细胞外囊泡生物标志物。
Biosens Bioelectron. 2013 Jun 15;44:115-21. doi: 10.1016/j.bios.2012.12.046. Epub 2013 Jan 2.
9
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.厄洛替尼对比化疗用于治疗晚期 EGFR 突变阳性非小细胞肺癌患者的一线治疗（OPTIMAL、CTONG-0802）：一项多中心、开放标签、随机、III 期研究。
Lancet Oncol. 2011 Aug;12(8):735-42. doi: 10.1016/S1470-2045(11)70184-X. Epub 2011 Jul 23.
10
Room-temperature hybridization of target DNA with microarrays in concentrated solutions of guanidine thiocyanate.
Biotechniques. 2003 Jun;34(6):1260-2. doi: 10.2144/03346mt01.
Zotero 插件